Novo, Lilly Fall as Trump Touts ‘Much Lower’ Ozempic Price

Novo Nordisk and Eli Lilly shares fell after President Donald Trump said the price of the blockbuster diabetes drug Ozempic could come down to just $150 a month.
The US list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month’s supply. Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.” Lilly sells similar treatments, including Mounjaro and Zepbound. “Those are going to be $150 out of pocket,” he said during a press conference in the Oval Office. That could lead to a big hit for Novo and Lilly, the two companies dominating the market Wall Street expects to top $95 billion by 2030. Bloomberg News Health Reporter Madison Muller joins Bloomberg Businessweek Daily to discuss. She speaks with Carol Massar and Bailey Lipschultz. (Source: Bloomberg)


Source link